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Abstract: The simplicity of object shape and composition modification make additive manufacturing 
a great option for customized dosage form production. To achieve this goal, the correlation between 
structural and functional attributes of the printed objects needs to be analyzed. So far, it has not 
been deeply investigated in 3D printing-related papers. The aim of our study was to modify the 
functionalities of printed tablets containing liquid crystal-forming drug itraconazole by introducing 
polyvinylpyrrolidone-based polymers into the filament-forming matrices composed predominantly 
of poly(vinyl alcohol). The effect of the molecular reorganization of the drug and improved tablets' 
disintegration was analyzed in terms of itraconazole dissolution. Micro-computed tomography was 
applied to analyze how the design of a printed object (in this case, a degree of an infill) affects its 
reproducibility during printing. It was also used to analyze the structure of the printed dosage forms. 
The results indicated that the improved disintegration obtained due to the use of Kollidon®CL-M 
was more beneficial for the dissolution of itraconazole than the molecular rearrangement and liquid 
crystal phase transitions. The lower infill density favored faster dissolution of the drug from printed 
tablets. However, it negatively affected the reproducibility of the 3D printed object.
Keywords: 3D printing; fused deposition modeling; hot-melt extrusion; solid dosage forms; itraconazole
1. Introduction
Additive manufacturing has huge potential to revolutionize the methods of drug delivery system
formation. It was proven for mass-scale drug production by Aprecia Pharmaceuticals, which registered 
the first 3D printed drug, Spritam®, in 2015. However, the use of additive manufacturing also enables 
the preparation of small batches of customized, on-demand-prepared formulations— for example, 
in the treatment of patients with rare diseases or for clinical trials. The great applicability of 3D printing 
(3DP) in the pharmaceutical field results from the simplicity of object shape modification, which allows 
the production of dosage forms of complex shape and internal structure, containing one or more active 
pharmaceutical ingredients (APIs) [1,2]. Moreover, the differences in shape and infill density of tablets,
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which cannot be achieved in compressed tablets, lead to alternation in the surface-to-volume ratio 
and allow us to produce printlets with desired drug dosages and dissolution profiles [3- 5]. Although 
the issue of the correlation between the internal structure of printed tablets and their properties, 
particularly the dissolution characteristics, has been explored by several research teams, there is still 
deficiency in studies on the actual microstructure and quality of printed objects and the mechanisms 
driving the release of the drug from printed dosage forms [6- 9].
In the case of nearly all 3DP methods, the object is built layer by layer based on the computer aided 
design (CAD) model. However, various printing technologies vary between each other regarding 
used materials and process conditions such as temperature. The 3D printing methods can operate 
with a powder, which is bound with a liquid binder or sintered with a laser, a photosensitive 
resin, a thermoplastic material, or a semi-solid formulation extruded through the printer nozzle. 
Several techniques, such as stereolithography [10- 14], selective laser sintering [8,15] digital light 
processing [16,17], binder jetting, [18,19], and extrusion-based methods including direct powder 
extrusion [20,21], semi-solid extrusion [22- 26], and fused deposition modeling (FDM) [27,28], have been 
investigated for application in the pharmaceutical industry. The 3DP methods which can be introduced 
in the high-scale manufacturing process should be characterized by the high-speed production of 
uniform objects [29,30]. In the case of most of the abovementioned printing methods, process conditions 
may cause amorphization of the active ingredient, which increases its solubility [31,32].
Various dosage forms, such as orodispersible films [33], mucoadhesive films [34], immediate 
and modified-release tablets [35,36], capsules [37,38], implants [39], or even formulations imitating 
sweets [40], have been recently developed using fused deposition modeling. In the printed dosage 
forms, drug release modification is obtained mostly by selecting either the filament-forming polymers 
characterized by suitable pH-dependent solubility [41] or the printlet shape and geometry, i.e., 
the presence of channels [42], empty cavities (floating tablets) [43,44], variations in the infill degree 
or shape as well as the use of shape-memory polymers to prepare retentive drug delivery systems 
(4D printing) [45,46]. Despite the fabrication of dosage forms by means of 3DP, this technique can 
be used for capsular shell fabrication [47] to control the API's dissolution process as well as mold 
preparation to create custom-made, patient-oriented drugs [48]. The 3D printed molds can be also 
used in a range of science and technology sectors including electrochemical electrical applications—for 
example, flexible sensor prototypes [49,50].
The application of FDM printing technology in the manufacturing of dosage forms requires the 
use of previously prepared drug-loaded filament. Filaments are produced mostly in the hot-melt 
extrusion process (HME), which is also the method applied to increase drug solubility. During this 
process, a mixture of drug and thermoplastic polymer is heated and blended, and the molten mass is 
pushed through a nozzle to form a filament [51]. Instead of drugs, other substances can be used in 
the HME process, e.g., insoluble hydroxyapatite for filament fabrication, which can be used in bone 
tissue engineering [52]. One of the most important advantages is that this process does not require 
the use of organic solvents, such as the preparation of amorphous solid dispersion (ASD) by spray 
drying. However, HME operates at high temperatures, which are required to melt the formulation 
components [53]. In some cases, it is necessary to add plasticizers to the formulation to lower the 
process temperature in order to protect the thermolabile active ingredient and improve filament 
printability [36,54,55]. The combination of HME and FDM can induce phase transitions, including 
amorphization, which results in increased drug solubility. Further drug dissolution modification can 
be also achieved by changing the shape and surface of the printed dosage form [26].
Itraconazole (ITR) is an oral antifungal agent used in the treatment of systemic and superficial 
fungal infections, commercially available in the form of 65 mg and 100 mg capsules, 200 mg tablets, 
and 10 mg/mL solutions. It is a highly lipophilic, weakly alkaline drug with very low water solubility 
of 1 ng/mL at pH 7 and 4 gg/mL at pH 1. ITR is classified as a Biopharmaceutics Classification System 
(BCS) class II substance [56], which means it has solubility-limited bioavailability. The drug exhibits 
three polymorphs varying in stability and solubility [57]. Moreover, ITR can form liquid crystals,
Materials 2020,13,4961 3 of 20
which are particularly interesting from the perspective of pharmaceutical sciences. Liquid crystals can 
adopt various molecular arrangements (nematic and smectic in the case of ITR), which affect the free 
energy of the system and thus the dissolution performance. Due to the relatively high glass transition 
temperature (Tg = 59 °C), ITR can be also transformed into a stable amorphous state, usually in the form 
of amorphous solid dispersions with polymers or co-amorphous systems with small molecules [58].
Soluplus® [59- 61], Eudragit® L [62], polyvinylpyrrolidone (PVP) [63], Kollidon® VA64 [64,65], 
polyvinyl alcohol (PVA) [65,66], as well as semi-synthetic cellulose derivatives such as hydroxypropyl 
cellulose [67] and hydroxypropyl methylcellulose acetate succinate [53,54,68- 70], are examples of 
pharmaceutical polymers tested for preparing itraconazole amorphous solid dispersions (ASD) and 
also suitable as filament-forming polymers for FDM. Although many papers described the formation 
of amorphous solid dispersions with ITR, including the use of the hot-melt extrusion process [61], 
only two considered the formation of dosage forms using 3D printing. Kimura et al. reported that it 
is possible to use fused deposition modeling to prepare zero-order sustained-release floating tablets 
containing itraconazole [43]. They were able to control floating time by printing tablets with empty 
cavities inside and to modify the drug dissolution rate by changing the tablet surface and wall thickness. 
Goyanes et al. prepared tablets containing amorphous solid dispersions of itraconazole in different 
grades of hydroxypropylcellulose using direct powder extrusion 3D printing— a novel, single-step 3D 
printing process. In contrast to FDM, this 3D printer tool head is equipped with single screw extruder, 
which allows it to print directly using mixed powders or pellets, without preparing filaments [20].
In this paper, we describe for the first time the liquid crystal phase transitions of itraconazole 
in 3D printed tablets. The drug was combined with polymers, formed into filaments via hot-melt 
extrusion and then printed using fused deposition modeling technology. The filaments were based 
on poly(vinyl alcohol), a water-soluble semi-crystalline polymer known for its superior printability. 
The two PVP-based polymers were also added to the filament-forming mixture to introduce the 
additional functionalities into the printed matrices. Kollidon® VA64 was supposed to modify the 
physicochemical properties—the molecular arrangement in particular (analyzed using thermal analysis 
and X-ray diffractometry)— and Kollidon® CL-M was added to modify drug dissolution due to the 
improved tablet disintegration. We performed deep micro-computed tomography (p-CT) analysis 
as the first attempt to analyze how the design of a printed object (degree of an infill) affects its 
reproducibility during printing. It was also used to analyze the structure of the printed dosage forms to 
support the dissolution data. To clearly understand the advantages of extrusion and printing processes, 
drug dissolution from printed formulations was compared with tablets having similar composition, 
obtained by the compression of either raw powders or milled filament.
2. Materials and Methods
2.1. Materials
Itraconazole (ITR, 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1 
-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one, 
99.8%, Henan Tianfu Chemical Co., Ltd., Zhengzhou, China) served as a model drug. Poly(vinyl alcohol) 
(PVA, Parteck® MXP, Merck®- KGaA, Darmstadt, Germany), copovidone (K/VA, Kollidon® VA64, 
BASF®, Ludwigshafen, Germany), crospovidone (K/CL, Kollidon® CL-M, BASF®, Ludwigshafen, 
Germany) were utilized as the matrix-forming polymers to prepare both filaments and 3D printed 
tablets. Talc (Fagron®, Kraków, Poland) and magnesium stearate (Avantor® Performance Materials, 
Gliwice, Poland) were added to tablets prepared by compression in tablet press. Hydrochloric acid 
(Merck® KGaA, Darmstadt, Germany) and potassium chloride (Avantor® Performance Materials, 
Gliwice, Poland) were used as dissolution media ingredients. Water used in all experiments was 
produced by Elix 15UV Essential reversed osmosis system (Merck® KGaA, Darmstadt, Germany).
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2.2. Preparation ofDrug-Loaded Filaments
Filaments were extruded using a 40D, 12-mm co-rotating twin-screw extruder (RES-2P/12A 
Explorer, Zamak Mercator®, Skawina, Poland) equipped with a gravimetric feeder MCPOWDER® 
(Movacolor®, Sneek, The Netherlands) and an air-cooled conveying belt (Zamak Mercator®, Skawina, 
Poland). The mixtures of itraconazolu and matrix-forming polymers, of the composi tion presented in 
Table °, and the tutal mass equal to 200 g weru extruded through a 1.75 mm die at 16)0 °C. The feeding 
rate was set to approximately 70 g/h, which resulted in the linear filament extrusion speed of 25 m/h. 
The barrel temporafiire varied from  40 to 190 i Ĉ . The optimized temperature profile and screw 
configuration are presented in Figure 1.
Table 1. Composition of the filaments.
Formulation Itraconazole Poly(vinyl alcohol) Copovidone Crospovidone
PVA 80% - -
PVA_K/VA 20% 56% 24% -
PVA_K/CL 76% - 4%
Figure 1. Screw configuration and temperature profile.
2.3. Evaluation o f  Filament Properties
The diameter uniformity o° the obtained filament was evaluated using a Mitutoyo®micrometer 
screw (Kawasaki, Japan). Six randomly selected points were measured. Meahpnical properties 
were assessed in stretching test performed with an EZ-SX tensile tester (Shimadzu®, Kioto, Japan). 
The measurements were performed six times for each type of  filament. Randomly selected pieces 
of filament:, 100 mm in length, weee placed in the tunsile tester's jaws and stretehed up to breakage. 
Hardness and elasticity of the filaments were determined based on the measurements of tensile strength 
and Young's modulus.
2.4. Determination o f  Itraconazole Content in the Obtained Filament
Six randomly selected and accurately weighed pieces of filament were placed in conical flasks 
filled with 25 mL of a mixture of methanol and 0.1 M HCl of pH 1.2 (1:1 v/v) and shaken for 24 h
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using a Memmert® water bath (WNB 22, Schwabach, Germany). The drug concentration was assayed 
at A = 255 nm using a Shimadzu® UV-1800 spectrophotometer (Kioto, Japan). The specificity of the 
analytical method was verified. There was no sign of interference between the drug and excipients at 
the analytical wavelength.
2.5. Preparation o f 3D Printed Tablets
The Blender® 2.79b software was used to design the models of the oblong tablets (Blender 
Foundation, Amsterdam, The Netherlands). The basic model was 20 mm long and 10 mm wide. 
The model height varied from 2.4 to 3.65 mm, which was related to the number of 3D printed layers. 
Voxelizer® slicing software (version 1.4.18, ZMorph®, Wroclaw, Poland) was applied to define the 
height and the width of the single layer path. The 3D model was imported in stl format and divided 
into layers before printing. The thickness of the first layer was equal to 0.2 mm to improve the adhesion 
of the print to the printer bed, whereas the height of the subsequent layers was 0.15 mm. The path 
width was equal to the diameter of the printing nozzle, i.e., 0.4 mm. One outline and rectilinear infill 
(density of 20%, 35%, and 60%) were designed for the printing process. Each tablet was composed 
of 50 mg of ITR and 200 mg of polymer carriers (Table 1). The tablets were printed by an FDM 
ZMorph® 2.0 S personal fabricator (Wroclaw, Poland) equipped with a 1.75 mm commercially available 
printhead. Printing temperature was 205 °C. The tablets were printed with a 10-15 mm/s printing 
speed. The temperature of building platform was 40 °C.
2.6. Preparation o f Tablets by Filament Compression (HME Tablets)
For comparison purposes, filament milled in a Tube Mill 100 control (IKA®, Staufen, Germany) 
and raw compounds were compressed in a Korsch® EK0 single-punch tablet press (Berlin, Germany). 
The composition of the tablets was similar to 3D printed tablets; each tablet was composed of 50 mg 
of ITR and 200 mg of polymer mixture. Additionally, the blends contained 12.5 mg of a talc and 
magnesium stearate mixture (9:1 w/w), which played the role of glidant and lubricant, respectively.
2.7. Preparation o f Directly Compressed Tablets (DC Tablets)
Powder blends composed of 3DP tablet ingredients with the addition of the talc and magnesium 
stearate mixture (9:1 w/w) were compressed using Korsch® EK0 single-punch tablet press (Berlin, 
Germany) for comparison purposes, to investigate the impact of technological processes on the ITR 
dissolution profile.
2.8. Micro-Computed Tomography
Micro-computed tomography (g-CT) analysis was performed using a SkyScan® 1172 
microtomograph (Bruker®, Billerica, MA, USA). It was applied to examine the structure of the 
3DP tablets with 20%, 35%, and 60% of infill and to verify the repeatability of printing process (the data 
collected for three tablets with 35% of infill were compared). The image pixel size was 6.9 gm for 
measurements of all samples. A cone beam reconstruction software program (Nrecon SkyScan®, 
Bruker®, Billerica, MA, USA) based on the Feldkamp algorithm was used for the reconstruction of 
the projections. A CT-Analyser® (SkyScan®, Bruker®, Billerica, MA, USA) was used for binarization 
purposes. The procedure was based on density distribution histograms collected for the whole sample 
volume. A CT-Analyser® was also used for the characterization of the morphological features of the 
tablets, their volume, and surface. CTVox® software (Bruker®, Billerica, MA, USA) was applied to 
present the 3D results.
2.9. Differential Scanning Calorimetry (DSC)
Thermodynamic properties of neat ITR, PVA, K/VA, K/CL, and their mixtures in the form of 
filaments and 3DP tablets were examined using a DSC 1 STARe System (Mettler-Toledo®, Greifensee,
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Switzerland) equipped with an HSS8 ceramic sensor with 120 thermocouples and liquid nitrogen 
cooling station. Zinc and indium standards were used for the temperature and enthalpy calibration. 
The samples were measured in an aluminum, pinned crucible (40 mL). The samples were heated 
with a rate of 10 K/min. The experiments were performed in nitrogen atmosphere with a gas flow of 
60 mL/min.
2.10. X-Ray Powder Diffraction (XRD)
A Rigaku Denki® D/MAX Rapid II-R (Tokyo, Japan) equipped with a rotating Ag anode and an 
image plate detector in the Debye-Scherrer geometry was used for the X-ray diffraction measurements. 
Graphite (002) crystal was used to monochromatize the incident radiation (AKa = 0.5608 A). The width 
of the X-ray beam at the sample was 0.3 mm. The samples were pulverized before the experiment 
and measured at room temperature, in glass capillaries with a diameter of 1.5 mm and wall 
thickness of 0.01 mm. The background intensity from empty capillary was subtracted. The obtained 
two-dimensional diffraction patterns were converted into one-dimensional functions of intensity versus 
the scattering vector.
2.11. Dissolution Studies
The dissolution of ITR from tablets was determined in 1000 mL of 0.1 M HCl with the addition of 
KCl, in the pharmacopeial paddle apparatus (Vision® G2 Elite 8, Hanson Research®, Chatsworth, CA, 
USA) equipped with a VisionG2 AutoPlus autosampler. Stainless steel, spring-like sinkers were used 
to prevent tablet floating. The samples were filtered and analyzed on-line at 255 nm at predetermined 
periods using a UV-1800 spectrophotometer (Shimadzu®, Kioto, Japan) equipped with flow-through 
cuvettes. Three repetitions for each sample were carried out. The results represent the averaged results 
and the standard deviations (mean ± SD).
2.12. Solubility Study
An excess of physical mixture (PM), extrudate (HME), and printed systems (3DP) were dispersed 
in 20 mL of 0.1 MHCl and shaken at ambient temperature using a KS 130 basic orbital shaker (IKA®, 
Staufen im Breisgau, Germany). After 48h, the samples were filtered through a 0.45 pm Chromafil® Xtra 
CA-45/25 membrane filter and analyzed spectrophotometrically at A = 255 nm (UV-1800 Shimadzu®, 
Kioto, Japan). The reported data represent the averages from three series of measurements with 
standard deviations (SD).
3. Results
3.1. Evaluation o f the Filaments
All prepared filaments were made using a PVA as a filament-forming polymer, a semi-crystalline 
polymer of molecular weight equal to 32 kDa with 87-89%  hydrolysis grade, having a glass 
transition temperature, melting point, and degradation temperature of 40-45 °C, 170 °C, and >250 °C, 
respectively [66]. The obtained itraconazole-loaded filaments were opaque and creamy in color. 
The diameter of the filaments was kept at a constant level; however, in the case of the PVA_K/CL 
filament, the diameter variations were higher than 0.05 mm, which is considered as a maximum 
acceptable deviation from the declared diameter [71]. The itraconazole content and its uniformity 
were satisfactory. All the API-loaded filaments were tested for their tensile strength and elasticity, 
which were found to be critical quality attributes in term of printability. The results are presented in 
Table 2 . It was found that the addition of copovidone and crosslinked PVP resulted in a decrease in 
the tensile strength and Young's modulus of the filaments. All the prepared filaments were able to 
be printed with a ZMorph® 2.0 S 3D printer immediately after extrusion and after storage in zipper 
storage bags.
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Table 2. Hot-melt extruded filament characteristics.
Filament
Composition
Diameter ± SD 
(mm)






PVA 1.70 ± 0 .02 19.67 =t 0.43 49.0 =t 10.3 2641.1 ± 144.4
PVA_K/CL 1.68 ± 0.07 19 .60 =t 0 .34 52.6 ± 19.8 2771.1 ± 347.2
PVA_K/VA 1.69 ± 0.05 19.20 =t 0.33 28.2 =t 7.1 2042.1 ± 256.3
In Figure 2, the differences in the mechanical characteristics are presented. Thr Young's modulus 
corresponds to the slope of the curve in the elastic behavior region.
Strain (%)
Figure 2. Comparison of the mechanical strength and resilience of the filaments.
3.2. Thermal and Structural Properties o f the Filaments and 3DP Tablets
To investigate how the employed polymers modify the thermal prope rties of neat ITR, the systeme, 
prepared in the form of both fflaments and 3 DP table ts, were measured rafter pulverization) by 
means of DSC. The samples were examined in the temperature r ange from 273 to 453 K at a heating 
rate of 10 K/min. In Figure 3, the obtained DSC traces are compared to the thermogram of the neat, 
quench-cooled ITR. Because the used PVA polymer has a lower glass transition temperature than ITR 
(Table 3) (Tg of neat PVA and ITR are equal to 313 and 332 K, respectively), the plasticization effect 
was observed. Interestingly, the DSC thermograms of the same compositions with different forms, 
filament or 3DP, differ from each other. As can be seen en Figure 3, rhe thermograms of the 3DP tablets 
are characterized by: (e) a shift in glass transition temperature towards lower values when comparen 
with filament: and (ii) the appearance op en additional, very broad endothermal event in rhe vicinity of 
320 to 420 K. The observed diffebences su ggest that the 3DP tablets also contain water in addition to 
API and po lymers. Water exerts a plastic izatron e ffect on the samples and ev aperates at te mperatures 
horn in tire range of 320 to 420 K.
W hen the neat ITR is heated above its glass transition temperature, on the DSC thermogram, 
one can distinguish two endothermal processes associated with the liquid crystal (LC) phase transitions. 
The thermal event located at 348 K reflects transition from smectic (Sm) to nematic (N) LC alignment, 
while at 364 K, ITR loses the nematic order and becomes an isotropic (I) liquid. The performed 
experiments reveal that the employed polymers shift to lower temperatures for both Sm-N and N-I 
phase transition. The determined, based on calorimetric studies, values of Tg, TSm-N, and TN-I for 
all investigated systems are compared in Table 3 . It is worth noting that in one of the examined 
systems (PVA_K/VA), regardless of the applied technological process, the lack of the nematic phase 
was observed (i.e., the N-I endothermal event was not registered by means of DSC).
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Temperature (K )
Figure 3. DSC thermograms of neat ITR and its mixtures with PVA, PVA_K/VA, and PVA_K/CL 
prepared in two forms: filament and 3DP tablet.
Table 3. Comparison of values of Tg , Tgm _N, and Tn -i  of neat ITR and its mixtures with PVA, PVA_K/VA, 
and PVA_K/CL which were prepared in two forms: filament and 3DP tablet.
Sample T  iK) Tsm-N (K) Tn-i (K)
Neat ITR :3:32> :3̂4:8 364
PVA filament 315 326 347
PVA 3DP tablet 306 330 344:
PVA_K/CL filament 312 329 346
PVA_K/CL 3DP tablet 308 330 344:
PVA_K/VA filament 317 328 (TSm-l)
PVA_K/VA 3DF> tablet 315 330 (Tsm-I)
In order to investigate whether the employed polymers indeed modify the ITR's LC alignment, 
both the neat ITR as well as the pulverized3DP tablets were measure d by wide-angle X-ray diffraction 
(XRD) technique. The comparison of the scattering patterns collected at room temperature for neat 
ITR and pulverized tablets containtng either PVA, PVA_K/VA, or PVA_K/CL is presented in Figure 4 . 
The presented XRD patterns demonstrate that the polymers affect the LC order in ITR. As can be seen, 
samples containing PVA or PVA_K/CL reveal less intense peaks at around 0.22, 0.45, and 0.68 A -1, 
which are indicators of smectic layering [72]. In the case of the system containing K/VA, the reduction in 
the intensity of the peaks at 0.22 and 0.68 A-1 is combined with the disappearance of the peak at 0.45 A-1 . 
These result s indi cate that the layered structure ire ITR is medicate d by the employed additives.
3.3. Micro-Computed Tomography Studies ofTeblets
The dimensions and masses of 3DP tablets corresponded to predefined values. The average tablet 
mass ranged from 239.73 to 253.05 mg. Tablet length varied from 19.85 to 20.15 mm, whereas height 
ranged from 1.78 to 3.65 mm. The real layer height was from 0.142 to 0.158 mm and was calculated 
by dividing the tablet height by the number of layers, given the fact that the first layer was 0.2 mm 
(Table 4). Digital photos of 3D printed tablets can be found in the Supplementary Materials associated 
with this article (Figures S1-S3, Supplementary Materials).
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Figure 4. XRD diffraction patterns of neat ITR and its mixtures with PVA, PVA_K/VA, and PVA_K/CL 
in an initial, form of 3DP tablet.
Table 4. Parameters of 3D printed tablets.
Polymers Infill (%) Mass (mg) Width (mm) Length (mm) Height (mm) Numb/r of Layers
Real Layer 
H eight (mm)
PVA 35 252.82 ± 4.16 10.18 s 0.03 20.15 ± 0.03 2.34 ± 0.03 1(5 0.S42
PVA_K/VA 35 253.05 ± 3.67 10.08 ± 0.01 20.0/ ± 0.01 2.89 ± 0.05 20 0.S42
PVA_K/CL S5 250.12 ± 4.52 9.98 ± 0.02 19.85 ± 0.12 2.67 ± 0.03 17 0.154
PVA_K/CL 20 244.12 ± 5.77 9.96) ± 0.03 19.86 ± 0.09 3.65 ± 0.03 24 0.150
PVA_K/CL 60 239.73 ± 3.01 9.99 ± 0.05 20.05 ± 0.03 1.78 ± 0.02 11 0.158
Based on the 3D tablet images obtained from Voxelizer slicin g software (I7igure 5) and predefined 
settings of the path size, thetheoretical volume of 3DP PVA_K/CL tablets was calculated. The values 
varied from 184.4 mm3 for T_20 tab lets to 195.6 mm3 for T_60 and 195.9 mm3 for T_35 tablets.
Figure 5. Images of PVA_K/CL tablet layers obtained from Voxelizer software.
The morphology of the PVA_K/CL printed tablets was verified by the pCT scans. Tablets; with 
20% of infsll had tine? highest object volume (236 mm3) and the highest open pore volume (485 mm3). 
Me dium more size (structure separation) was 1.11 mm, whereas the avesage structure thickness was 
0.25 mm. Tablets with 60% ofinfill were characterized by the lowest values of object volume (202 mm3) 
and pore bolume (134 mm3) as well as structuse separation (0.19 mm) and pore size (0.25 mm). 
Aforementioned parameters for tablets with 35% of infill can be placed between T_20 and T_60 values 
(Table 5, Figure 6) .
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Table 5. Comparison of pCT scan data of 3DP PVA_K/CL tablets with 20% (T_20), 35% (T_35), and 60% 
(T_60) infill ratio.
Description Unit T_20 T_35 T_60
Object volume mm3 236 220 202
Percent object volume °/% 33 41 60
Structure thickness mm 0.25 0.20 0.19
Structure separation mm 1.11 0.62 0.25
Volume of open pore space 3mm3 485 312 134
Open porosity °/% 67.2 58.5 39.9
Figure 6. 3D tablet models, p-CT scan images of 3DP tablets, and structure thickness and structure 
separation of 3DP tablets.
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Parameters of tablets with 35% of infill are similar and no important differences between the three 
analyzed tablets can be distinguished (Table 6, Figure 7).
Table 6. Comparison of pCT scan data of 3DP PVA_K/CL tablets with 35% of infill ratio.
Description Unit T 3 5  1 T_35_2 T_35_3
Object volume mm3 220 224 213
Percent object volume °/% 41 42 39
Structure thickness mm 0.20 0.19 0.17
Structure separation mm 0.62 0.62 0.62
Volume of open pore space mm3 312 307 327
Open porosity °/% 58.5 57.7 60.4
Figure 7. Comparison of 3DP tablets with 35% of infill.
3.4. Dissolution Studies
Itraconazole dissolution from 3D printed tablets with 35% infill was compared with the dissolution 
profiles obtained for the tablets made from milled extrudate (HME tablets) and directly compressed
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tablets (DC tablets) to evaluate the impact of the excipients and hot-melt extrusion on the dissolution of 
the API. Determined itraconazole solubility limits were equal to 5.8, 22.2, and 29.3 pg/mL for physical 
mixture, extrudate, and 3D printed matrix, respectively. The solubility limits were calculated as the 
percentage of ITR dose in tablets (11.6%, 44.4%, and 58.6% for physical mixture, extrudate, and 3D 
printed tablet, respectively) and are marked in Figure 8 to make the interpretation of the dissolution 
easier. It was found that the performed technological processes, namely hot-melt extrusion and 3D 
printing, affected the dissolution profile of itraconazole. The highest amount of the drug was dissolved 
from 3D printed tablets. The amount of ITR released from milled extrudate was significantly lower, 
while th e  smallest amount was released from directly compressed tablets (Figure 8). After 2 h of 
the dissolution test, 75.8%, 51.3%, and 11.0% of the itraconazole was released from the PVA-based 
3D printed, hot-melt extruded, and directly compressed tablets, respectively. This relationship was 
confirmed for all the prepared formulations. It must be highlighted that in the case of all 3D printed 
formulations, i .e., PVA, PVA_K/VAt and PVA_K/CL, tire amount of dissolved itraconazole was far 
above the solubility limit and the supersaturation lasted as long as the dissolution test was performed.
Figure 8. The influence of the; technological process on the release profiles of itraconazole from
PVA-based tablets (infill density equal to 35%).
The impact of copovidone and crospovidone addition to the PVA formulation on the telease 
profile was also evaluated (Figure 9). The best dissolution profile was noticed for PVA_K/CL 3D 
printed tablets. After 45 min, 91.5% of the API was dissolved from PVA_K/CL 3D printed tablets, 
while only 64.3% and 46.7% of tine drug was released from 3D printed tablets with Kollidon® VA64 
and PVA-bastd tablets, respectively.
The impact of the infill density on the dissolution characteristics was evaluated for the PVA_K/CL 
formulation (Figure 10) as it was selected as the most promising formulation from all the prepared 
3D printed tablets. Three rectilinear infills with different densities, namely 20%, 35%, and 60%, 
were evaluated. The results confirmed that the lower infill density favored faster dissolution of the 
API. After 45 min of the dissolution test, 96.9%, 89.7%, and 80.9% of the itraconazole was released from 
3D printed tablets with 20%, 35%, and 60% infill, respectively.
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Figure 9. Theinfluence olr the oxctpients on d issolution pro files of itraconazole from 3DP tablets (infill 
density equal to 35%).
Time (min)
Figure 10. The influence oT infill percentage on dissolution profiles of firaconazole from 3DP tablets.
4. Discussion
The filament extrusion went smoothly, and it can be carried ouf as a continuous manufacturing 
process. As a result of the optimization o f  the barrel temperature profile, genera ned torque, which may 
be considered as one of the major limitations during the extrusion, was as low as 2.82 ± 0.09 fern during 
the filament extrusion process. All the prepared filaments were of satisfying; quality and were printable 
using a ZMorph® 2.0 S 3D printer. PVA-based filamente were characterized by the most uniform 
diameter which may eesult from the simplest composition of the filament. Copovidone (K/VA) was 
added te the filament formulation to improve -tine solubility of the drug in fhe polymer matrix as it was 
shown by W łodarski et al. [65], while crosslinked PVP (K/CL) was added to improve disintegration 
and API dissolution from the extrudates and 3D printed tablets t The elasticity of the filaments was 
evaluated based on fhe Young's modulus values. The values obtained for itraconazole-loaded fslaments 
were in the rangs 2042.1-2641.1 MPa and they were comparable to the results obtained by Feuerbach et 
al. for Resomer filaments [73]. Then filament elasticity was not: significantly affected bye the addition of 
either copovidone or crospovidone )o the formulation, while the values of the Young's modulus varied 
in the narrow range. However, it was found that the fflament with tire addition of copovidone was
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characterized by slightly higher elasticity than the one composed of only PVA or PVA-K/VA filaments. 
The obtained Young's modulus values for all prepared filaments suggest that they are suitable for 
fused deposition modeling 3D printing. The tensile strength was in the range from 28.2 to 52.6 MPa; 
the lowest value was obtained for the filament with the addition of Kollidon®VA64. Its introduction to 
the polymer matrix caused a more than 1.7-fold decrease in tensile strength in comparison with the 
itraconazole-loaded PVA filament. This may result from the Kollidon®VA64 extrudate's brittleness, 
which was confirmed by Fuenmayor et al. [74]; however, it was still durable enough to be printed.
A set of 10 X 20 mm2 oblong tablets with different infill densities was printed with good 
repeatability. The tablets were uniform in shape and mass. The dimensions of the 3DP tablets were 
similar to predefined 3D objects. The adjustment of tablet height and, in consequence, the number 
of layers was related to the filament properties to obtain tablets with comparable mass (Table 4). 
The differences in tablet mass did not exceed 12.5 mg (±5%) from the theoretical value of 250 mg.
The theoretical tablets' volume was compared to the real object volume of 3DP PVA_K/CL tablets 
with infill of 20%, 35%, and 60% (Table 5), determined during the pCT scan. In the case of 20% 
of infill tablets (T_20), the real tablet volume was almost 1.3 times higher than calculated. This is 
related to the morphology of tablets with low infill density. The substantial distance between infill 
cross-points, in which two adjacent layers adhere, resulted in overhangs without support. It led to 
path disorder and an increase in vertical layer dimension. Therefore, subsequent cohesion in some 
spaces between cross-points was observed (Figure 6). In the case of T_35, the difference in tablet 
volume was smaller (1.12 times higher) whereas the volumes of T_60 tablets were similar (1.03 times 
higher). This improvement was related to the higher density of tablets' infill with increasing number 
of cross-points.
The phenomenon of path expansion between the cross-points can also be explained by the 
deviations of the structure thickness parameter in comparison with the theoretical value of 0.15 mm. 
This effect was observed for all degrees of infill; however, it was less pronounced in the systems 
with the higher infill density (Figure 6). The biggest difference was noticed in the case of T_20 
tablets, for which the mean structure thickness was 100 pm higher than the theoretical layer height. 
For T_35 and T_60 tablets, the structure thickness was 40-50 pm higher. The differences in the structure 
thickness distribution are presented in Figure 6 . The widest span of structure thickness was noticed 
for T_20 tablets and the structures with 0.25-0.35 mm thickness had the greatest volume within 3DP 
objects. On the contrary, the T_60 tablets exhibited the narrowest span, with structures of thickness 
varying between 0.15 and 0.25 mm highly represented within the object (Figure 6). Structure thickness 
distribution among a set of T_35 tested tablets was similar and showed good repeatability of printed 
dosage forms with 35% of infill (Table 6, Figure 7). Moreover, identical mean structure separation was 
observed within all T_35 tablets (Table 6) The porosity within T_35 tablets was similar, and histograms 
of structure separation distribution revealed that pores with size 0.8-1.0 mm are highly represented 
(Figure 7 ). Decreasing the tablet infill from 35% to 20% resulted in porosity changes. Pores with 
larger sizes, between 1.2 and 1.75 mm, are visible on the histograms and the total porosity increased 
from 58.5% to 67.2%. In the case of T_60 tablets, pore size did not exceed 0.5 mm and total porosity 
was almost 1.7 times smaller (39.9%) than T_20 (Figure 6). It should be emphasized that the volume 
of the open pore space within the 3DP T_20 tablet (485 mm3) is twice as high as the volume of the 
solid part of the tablet (236 mm3), whereas the volume of the open pore space of T_60 (134 mm3) is 
1.5 times smaller than the solid part of the tablet (202 mm3). The tablet open space will promote the 
penetration of dissolution media through the tablet's internal structure and will have an impact on its 
disintegration and dissolution behavior. The influence of the internal structure of 3D printed objects 
on their properties was highlighted and widely discussed by Nazir et al. in the comprehensive review 
of the various 3D printed lattice and cellular structures, their advantages and limitations [75].
The results of the dissolution studies indicate that the 3D printing process improved itraconazole 
release when compared with tablets made by compression with either milled extrudate or a simple 
powder blend. This should be attributed to the developed internal structure and resulting extended
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surface area as well as the molecular rearrangement in the structure of API within the polymer matrix. 
Itraconazole release was faster from tablets containing added copovidone than PVA alone because 
the hot-melt extrusion and following 3D printing led to the formation of more disordered systems, 
which was confirmed by the lower intensity of the characteristic peaks in the XRD diffractograms 
and the lack of the nematic phase confirmed by DSC in the PVA_K/VA 3DP tablets. The release of 
itraconazole from filaments and 3D printed tablets containing only PVA was lower than from the 
corresponding systems containing the additive of PVP-based polymers since its structure was more 
ordered, as indicated by the presence of smectic and nematic domains. It is worth mentioning that the 
improved drug dissolution results from the applied technological processes, not just the addition of the 
polymers. The results of the dissolution from directly compressed tablets revealed that the presence of 
the polymers themselves did not enhance the dissolution of itraconazole as the amount of dissolved 
API did not exceed 12% of the initial dose.
The results indicated that the addition of the disintegrant, i.e., crospovidone, to the 3D printed 
tablets is beneficial in terms of ITR dissolution. The addition of the disintegrant to the formulation led 
to a higher increase in API dissolution than adding a copovidone to achieve molecularly disordered 
material. With the presented results, we have demonstrated that the PVA_K/CL formulation is the 
most promising in terms of immediate-release tablet preparation, as it is characterized by the best 
dissolution profile. Subsequent optimization was performed to evaluate the possibility of further 
improvement of itraconazole release. The optimization included changes in the infill density, as it 
was confirmed by many research groups that infill density significantly affects the dissolution rate of 
the API [76] . The tablets with infill density of 20%, 35%, and 60% were successfully 3D printed and 
tested. As predicted, lower infill density resulted in faster dissolution. However, the micro-computed 
tomography imaging revealed that during the printing of the tablets with 20% infill, there was an issue 
with maintaining the internal structure geometry, which also manifested in higher deviations in the 
amount of dissolved itraconazole in the first 20 min of the dissolution test (Figure 10). The tablets with 
60% infill were characterized by the slowest itraconazole release. This is directly connected with the 
difficulty of water penetration into the tablet due to the smaller pores and channels in the internal 
structure. Therefore, we chose 35% infill as the best formulation to evaluate the tablet shape, dose, 
and internal structure reproducibility in the 3D printing process. In all cases of 3D printed tablets, 
long-lasting supersaturation of the itraconazole was achieved. It is well-known that the persisting 
state of supersaturation may lead to bioavailability improvements, which is especially beneficial in 
terms of poorly soluble drugs such as itraconazole [77].
5. Conclusions
Our study has shown the detailed methodology for the development of immediate-release 3D 
printed tablets with liquid crystal-forming itraconazole. The development stage included both the 
optimization of the formulation composition and the correlation between the geometry of the printed 
object, namely the degree of infill, with shape reproducibility and drug dissolution.
The use of well-printable PVA polymer alongside the functionalized excipients, i.e., polyvinylpyrrolidone 
derivatives, during the hot-melt extrusion process covered not only the optimization of the mechanical 
properties of the filament and its printability but also the function of the polymer matrix in terms 
of intended drug release profiles. The results of the dissolution study and physicochemical analysis 
indicated that improved disintegration obtained due to the use of Kollidon®CL-M was more beneficial 
than the molecular rearrangement and liquid crystal phase transitions. The lower infill density favored 
faster dissolution of the drug from printed tablets.
Micro-computed tomography was utilized to confirm that the design of printed objects was 
properly reconstructed. The comprehensive analysis revealed that the infill density, which is often 
considered as a way to control or improve drug dissolution, should be utilized with a deep 
understanding of its effect on the 3D printed objects' reproducibility. In the case of low infill densities, 
reproducibility issues, i.e., path disorder, increased layer dimension, and the path cohesion between
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cross-points, may occur. On the contrary, dense infill limits the surface area available for dissolution 
media and slows down the dissolution of the API.
In the case of the presented results, the most appropriate properties, i.e., good reproducibility 
during the object printing combined with superior drug dissolution, were achieved for the filament
composed of 20% of itraconazole, 76% of PVA, and 4% of crospovidone acting as a disintegrant.
Supplementary Materials: The following are available online at http://www.mdpi.com/1996-1944/13/21/4961/s1, 
Figure S1: 3D printed itraconazole-loaded tablet with 20% infill density; Figure S2: 3D printed itraconazole-loaded 
tablet with 35% infill density; Figure S3: 3D printed itraconazole-loaded tablet with 60% infill density.
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